Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Net Income

Bottom-line profit after all expenses, interest, and taxes.

Evotec SENASDAQ: EVO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -€123.94M, compared with -€31.58M a year earlier. Trailing-twelve-month net income was -€196.02M.

Context

  • Net income amounted to 13.1% of revenue in FY2025, down 11.5 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -€254.23M (-155.7%) for the fiscal year ending Dec 2026, a slowdown from the +49.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€123.94M-955.5% QoQ
Last fiscal yearDec 2025
-€99.43M+49.3% YoY
LTMMar 2026
-€196.02M+5.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-292.5%+71.4%+363.9 pp
1 year+49.3%-155.7%-205.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
(99.43M) EUR
Year-over-year change
+49.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.3% is the 5th highest of 11, against a peer median of -7.5%.
  • Net income amounts to 26.3% of revenue for EVO, versus a peer median of 22.0%.
EVO Competitors
Net Income for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCRXPacira BioSciences, Inc.LTM Mar 2026$5.14M USD+105.0%-23.8%0.7%
HROWHarrow Health, Inc.LTM Mar 2026-$14.96M USD+31.0%—5.6%
SDGRSchrödinger, Inc.LTM Sep 2026-$59.25M USD+66.3%—22.0%
ALVOAlvotechLTM Mar 2026-$80.73M USD-183.6%—14.4%
AZTAAzenta, Inc.LTM Sep 2026-$166.99M USD-212.8%—26.9%
TDOCTeladoc Health, Inc.LTM Mar 2026-$171.15M USD+83.1%—6.8%
NVCRNovoCure LimitedLTM Mar 2026-$173.05M USD-5.4%—25.7%
PHVSPharvaris N.V.LTM Sep 2026-€181.84M EUR-9.5%——
EVOEvotec SELTM Mar 2026-€196.02M EUR+5.3%—26.3%
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$263.86M USD-77.1%—291.6%
TLRYTilray Brands, Inc.LTM Feb 2026-$1.85B USD-36.2%—156.2%
Peer median (excluding EVO) —-7.5%-23.8%22.0%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue618.03M751.45M781.43M796.97M757.26M
Cost of Revenue466.49M577.38M606.38M682.09M694.6M
Gross Profit151.54M174.07M175.05M114.88M62.66M
Gross Margin24.5%23.2%22.4%14.4%8.3%
Research & Development65.7M76.64M68.53M50.86M74.33M
Selling, General & Admin105.45M156.19M169.61M188.2M123.65M
Operating Expenses110.55M153.22M222.56M257.4M197.97M
Depreciation & Amortization70.4M83.2M92.98M101.62M95.55M
EBITDA316.63M(57.61M)24.13M(80.66M)(13.89M)
EBITDA Margin51.2%-7.7%3.1%-10.1%-1.8%
Operating Income41M20.85M(47.51M)(142.52M)(135.31M)
Operating Margin6.6%2.8%-6.1%-17.9%-17.9%
Interest Income2.27M8.34M9.26M2.44M4.25M
Interest Expense9.25M13.15M11.74M11.7M13.87M
Other Income / Expenses195.98M(174.81M)(33.09M)(51.46M)12M
Income Before Tax236.98M(153.96M)(80.59M)(193.98M)(123.31M)
Pre-Tax Margin38.3%-20.5%-10.3%-24.3%-16.3%
Income Tax Expense21.47M21.7M3.32M2.1M(23.88M)
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Net Margin34.9%-23.4%-10.7%-24.6%-13.1%
EPS (Basic)0.65(0.49)(0.23)(0.56)(0.28)
EPS (Diluted)0.65(0.49)(0.23)(0.56)(0.28)
Weighted Avg Shares332.81M353.35M353.87M353.29M355.16M
Weighted Avg Shares (Diluted)332.81M353.41M353.87M354.59M355.16M

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.